• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:马玲玲,赵兰婷,刘慧,孙明伟,卢雪明,王春芳,杨迎迎,尹宁宁,武海军.已上市中药生产工艺变更共性问题探讨及对策分析[J].药学研究,2025,44(3):302-306,312[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2214次   下载 799次 本文二维码信息
码上扫一扫!
已上市中药生产工艺变更共性问题探讨及对策分析
马玲玲,赵兰婷,刘慧,孙明伟,卢雪明,王春芳,杨迎迎,尹宁宁,武海军
字体:加大+|默认|缩小-
(山东省食品药品审评查验中心,山东 济南 250014)
摘要:
目的 了解已上市中药生产工艺变更的现状和亟需解决的问题,为持有人科学规范开展已上市中药变更研究以及监管部门进行技术审查和监管提供参考。方法 通过对山东省已上市中药生产工艺变更过程中的疑难问题进行梳理汇总,分析可能存在的风险和问题,并针对科学规范开展中药生产工艺变更、合理解决问题、有效控制风险进行探讨并提出意见建议。结果 本研究结果显示,药品上市许可持有人在中药生产工艺变更过程中存在变更研究验证不充分、变更分类不合理、研究资料缺陷等问题。结论 本研究从加强中药生产工艺变更管理提出了合理化建议。药品上市许可持有人应充分履行其主体责任,加强药品质量管理体系建设,借助先进生产技术,持续提升产品质量控制水平,合理开展中药制剂生产工艺变更;药品监督管理部门可通过采取宣贯、培训、案例分享等方式强化监管服务,提升监管人员业务能力水平。
关键词:  已上市中药  生产工艺变更  变更管理  问题分析  意见建议
DOI:10.13506/j.cnki.jpr.2025.03.015
基金项目:
出版日期:2025-03-25
Exploration and analysis of common problems and countermeasures inthe change of production process of listed Chinese traditional medicine
MA Lingling,ZHAO Lanting,LIU Hui,SUN Mingwei,LU Xueming,WANG Chunfang,YANG Yingying,YIN Ningning,WU Haijun
(Shandong Center For Food and Drug Evaluation Inspection,Jinan 250014,China)
Abstract:
Objective To understand the current status and urgent issues to be solved in the change of production process of listed traditional Chinese medicine,providing references for scientific and standardized research on the change of listed traditional Chinese medicine conducted by holders and for the technical review and supervision by regulatory authorities. Methods By sorting out and summarizing the difficult problems in the process of changing the production process of listed traditional Chinese medicine in Shandong Province, analyzing the possible risks and problems, and in view of the scientific and standardized Chinese medicine production process changes and reasonable to solve the problem, discusses the effective control of risks and advice were put forward. Results The results of this study indicate that holders of drug marketing authorization have problems such as insufficient verification of change research, unreasonable classification of changes, and deficiencies in research data during the process of traditional Chinese medicine production process changes. Conclusion This study puts forward reasonable suggestions from strengthening the management of TCM production process change.The holder of drug marketing authorization should fully fulfill its main responsibilities,Strengthen the construction of drug quality management system, leverage advanced production technology, and continuously improve the level of product quality control,reasonably carry out changes in the production process of traditional Chinese medicine preparations;Drug regulatory departments can strengthen regulatory services by adopting publicity and implementation, training, case sharing and other ways to improve the business ability of regulatory personnel.
Key words:  Listed traditional Chinese medicine  Change of production process  Change management  Problem analysis  Comments and suggestions
今日访问量:2656    总访问量:55339172
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司